DANVERS, Mass., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced that data from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP™ (Right Peripheral) System, will be released during the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2014 scientific meeting.
The presentation, "A Prospective, Multicenter Study to Evaluate a New Percutaneous Ventricular Assist Device for Right Ventricular Failure: The RECOVER RIGHT Study," will take place at 5:00 p.m. on Tuesday, September 16 in Room 147A at the Walter E. Washington Convention Center. The data will be presented during the session, Didactic Symposia: Interventional Innovation IV - Late-Breaking Early Human Clinical Studies and Reports, by William O'Neill, M.D., Co-Principal Investigator for the RECOVER RIGHT trial. Mark Anderson, M.D. is also Co-PrincipaI Investigator for the trial.
The Company is also announcing that it has completed its FDA submission of RECOVER RIGHT trial data for the Human Device Exemption (HDE) submission.
*The Impella RP is currently the subject of an investigational device exemption (IDE) clinical study and is limited by federal law to investigational use.
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
CONTACT: For further information please contact: Aimee Genzler Director, Corporate Communications 978-646-1553 firstname.lastname@example.org